Accurate diagnosis of soft tissue tumors is critical for appropriate therapy. Over-diagnosis (interpretation of a benign entity as malignant) may lead to aggressive and unnecessary surgical procedures, while under-diagnosis (interpretation of a malignant tumor as benign) may result in higher recurrence rates, metastases and potentially a second more mutilating surgery. Soft tissue tumors are a large and diverse group of rare neoplasms representing less than 1% of adult solid tumors, and the majority of general surgical pathologists do not encounter these specimens on a regular basis.
This highly respected faculty offers you the opportunity to experience a panorama of challenging soft tissue lesions that you might not otherwise encounter in your practice. Learn from the best how to diagnose and classify them, what are the genetic and molecular characteristics emerging from soft tissue tumor subtypes, and what you need to become skilled at diagnosing, or at least triaging, these unusual lesions. Target Audience
Practicing academic and community pathologists, and pathologists-in-training Learning Objectives
Upon completion of this educational activity, learners will be able to:
- Review the morphology of a comprehensive set of benign and malignant soft tissue tumors
- Recognize key features of common benign entities to avoid misclassification as malignant
- Understand basic principles in working up lipomatous, peripheral nerve sheath and smooth muscle tumors
- Recognize common mimics of sarcomas including sarcomatoid carcinoma and spindle cell melanoma
- Understand the rationale for molecular testing in soft tissue tumors
The United States and Canadian Academy of Pathology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The United States and Canadian Academy of Pathology designates this enduring material for a maximum of 12.25 AMA PRA Category 1 CreditsTM
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The USCAP is approved by the American Board of Pathology (ABPath) to offer Self-Assessment credits (SAMs) for the purpose of meeting the ABPath requirements for Continuing Certification (CC). Registrants must take and pass the post-test in order to claim SAMs credit.
Physicians can earn a maximum of 12.25 SAM credit hours.
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to USCAP and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. USCAP has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.
The following faculty reported no relevant financial relationships: Karen Fritchie, M.D., Sarah Dry, M.D. , Andrew Folpe, M.D., Andrew Horvai, M.D., Ph.D.
USCAP staff associated with the development of content for this activity reported no relevant financial relationships.